{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:51:39Z","timestamp":1767649899041,"version":"3.44.0"},"reference-count":29,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"published-print":{"date-parts":[[2010]]},"abstract":"<jats:p>We report a case of a 25-year-old woman with chronic myeloid leukaemia who was randomised to dasatinib 100 mg orally daily in a clinical trial. The patient was advised to avoid pregnancy while on treatment due to its teratogenic potential. Five months later, the patient was found to be 6 weeks pregnant. Once pregnancy was confirmed, dasatinib was immediately stopped and the patient was taken off the trial. She was managed conservatively during the remainder of her pregnancy with close observation only. She delivered a healthy infant at 37 weeks' gestation without any documented birth defects. Dasatinib has been shown in animal studies to cause fetal toxicities, but the effect of exposure during conception and pregnancy in humans is not known. We provide a full report of a successful pregnancy in a patient who was exposed to dasatinib during the first trimester; we also give a brief literature review.<\/jats:p>","DOI":"10.1136\/bcr.05.2010.2975","type":"journal-article","created":{"date-parts":[[2010,10,21]],"date-time":"2010-10-21T12:18:42Z","timestamp":1287663522000},"page":"bcr0520102975","source":"Crossref","is-referenced-by-count":14,"title":["Successful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester"],"prefix":"10.1136","volume":"2010","author":[{"given":"Soley","family":"Bayraktar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belline","family":"Morency","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maricer P","family":"Escal\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2010,10,21]]},"reference":[{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.1","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.4.1.85"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.2","unstructured":"Wetzler M Bloomfield CD . Acute and chronic myeloid leukemia. In: Fauci Braunwald Isselbacher Wilson , eds. Harrison's Principles of Internal Medicine. 17th Edition. Vol I. 2008:677\u201386."},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.3","doi-asserted-by":"publisher","DOI":"10.1126\/science.132.3438.1488"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.4","first-page":"1013","article-title":"Chromosome studies in human leukemia. II. Chronic granulocytic leukemia","volume":"27","author":"Nowell","year":"1961","journal-title":"J Natl Cancer Inst"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa062867"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.7","unstructured":"NCCN. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. PA Fort Washington: NCCN 2009."},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.8","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2368"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(01)00197-7"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.10","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2147"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.84"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.13","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.221"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.14","doi-asserted-by":"crossref","unstructured":"Cortes J O'Brien S Borthakur G . Efficacy of dasatinib in patients with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CMLCP). Blood 2008;112:Abstract 182.","DOI":"10.1182\/blood.V112.11.182.182"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.15","first-page":"147","article-title":"Successful management of chronic myeloid leukaemia with leucapheresis during a twin pregnancy","volume":"65","author":"Klaasen","year":"2007","journal-title":"Neth J Med"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.16","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0412.2000.079009803.x"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.17","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2141.1992.tb08202.x","article-title":"Interferon-alpha therapy during pregnancy in chronic myelogenous leukaemia and hairy cell leukaemia","volume":"81","author":"Baer","year":"1992","journal-title":"Br J Haematol"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.18","unstructured":"GLEEVEC (imatinib mesylate) [Important Safety Information]. NNPC: East Hanover, 2001."},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.19","unstructured":"Tasigna (nilotinib) [Important Safety Information]. NNPC: East Hanover, 2007."},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.20","unstructured":"Sprycel (dasatinib) [Important Safety Information]. NB-MS: Princeton, 2007."},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6557"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-114900"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.23","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.064"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.05.012"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.25","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.022764"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.26","doi-asserted-by":"crossref","unstructured":"Conchon M Sanabani SS Serpa M . Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on Dasatinib therapy. Adv Hematol 2010:1\u20134.","DOI":"10.1155\/2010\/136252"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.27","doi-asserted-by":"crossref","unstructured":"Oweini H Otrock ZK Mahfouz RA . Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet 2010. doi: 10.1007\/s00404-010-1501-6","DOI":"10.1007\/s00404-010-1501-6"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.28","doi-asserted-by":"crossref","unstructured":"Cortes J O'Brien S Ault P . Pregnancy outcomes among patients with chronic myeloid leukemia treated with Dasatinib. Blood 2008;112:Abstract 323.","DOI":"10.1182\/blood.V112.11.3230.3230"},{"key":"2025082703500622000_2010.oct18_2.bcr0520102975.29","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-2-42"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr.05.2010.2975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:50:17Z","timestamp":1756291817000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr.05.2010.2975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":29,"alternative-id":["10.1136\/bcr.05.2010.2975"],"URL":"https:\/\/doi.org\/10.1136\/bcr.05.2010.2975","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2010]]}}}